Twice-daily dosing of dolutegravir in infants on rifampicin treatment: a pharmacokinetic substudy of the EMPIRICAL trial.

Tom G JacobsVivian MumbiroUneisse CassiaKevin ZimbaDamalie NalwangaAlvaro BallesterosSara Domínguez-Rodríguez Alfredo TagarroLola MadridConstantine MutataMoses ChitsamatangaMutsa Bwakura-DangarembiziAlfeu PassanducaW Chris BuckBwendo NdunaChishala ChabalaElizabeth NajjingoVictor MusiimeCinta MoraledaAngela ColbersHilda A MujuruPablo RojoDavid M Burgernull null

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)

Dolutegravir twice-daily in infants receiving rifampicin-based TB-treatment resulted in adequate dolutegravir exposure, supporting this treatment approach for infants with HIV-TB coinfection.

Keyphrases

mycobacterium tuberculosis
antiretroviral therapy
clinical trial
physical activity
hiv infected patients
hiv infected
study protocol
hiv aids
pulmonary tuberculosis
south africa
phase iii
phase ii
double blind